These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9081681)

  • 1. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia.
    Bröijersén A; Eriksson M; Leijd B; Angelin B; Hjemdahl P
    Arterioscler Thromb Vasc Biol; 1997 Feb; 17(2):273-8. PubMed ID: 9081681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia.
    Notarbartolo A; Davì G; Averna M; Barbagallo CM; Ganci A; Giammarresi C; La Placa FP; Patrono C
    Arterioscler Thromb Vasc Biol; 1995 Feb; 15(2):247-51. PubMed ID: 7749833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
    Schrör K; Löbel P; Steinhagen-Thiessen E
    Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of treatment with oral isosorbide dinitrate on platelet function in vivo; a double-blind placebo-controlled study in patients with stable angina pectoris.
    Wallén NH; Andersson A; Hjemdahl P
    Br J Clin Pharmacol; 1994 Jul; 38(1):63-70. PubMed ID: 7946939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia.
    Bröijersén A; Eriksson M; Angelin B; Hjemdahl P
    Arterioscler Thromb Vasc Biol; 1995 Jan; 15(1):121-7. PubMed ID: 7749807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased thromboxane biosynthesis in type IIa hypercholesterolemia.
    Davì G; Averna M; Catalano I; Barbagallo C; Ganci A; Notarbartolo A; Ciabattoni G; Patrono C
    Circulation; 1992 May; 85(5):1792-8. PubMed ID: 1572035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metoprolol does not reduce platelet aggregability during sympatho-adrenal stimulation.
    Larsson PT; Olsson G; Angelin B; Granström E; Hansson G; Hjemdahl P
    Eur J Clin Pharmacol; 1992; 42(4):413-21. PubMed ID: 1387607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients.
    Lansberg PJ; Mitchel YB; Shapiro D; Kastelein JJ; Altman R; Jerums G; Bolzano K; Giannini S; Davignon J; DeWailly P
    Atherosclerosis; 1995 Aug; 116(2):153-62. PubMed ID: 7575771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia.
    Chan P; Huang TY; Tomlinson B; Lee C; Lee YS
    J Clin Pharmacol; 1997 Jun; 37(6):496-501. PubMed ID: 9208356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
    Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G
    Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
    Walker JF; Shapiro DR
    Am J Cardiol; 1990 Mar; 65(12):19F-22F. PubMed ID: 2180267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E.
    De Caterina R; Cipollone F; Filardo FP; Zimarino M; Bernini W; Lazzerini G; Bucciarelli T; Falco A; Marchesani P; Muraro R; Mezzetti A; Ciabattoni G
    Circulation; 2002 Nov; 106(20):2543-9. PubMed ID: 12427649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
    Thiery J; Creutzfeldt C; Creutzfeldt W; Walli AK; Seidel D
    Klin Wochenschr; 1990 Aug; 68(16):814-22. PubMed ID: 2214604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.
    Thomas ME; Harris KP; Ramaswamy C; Hattersley JM; Wheeler DC; Varghese Z; Williams JD; Walls J; Moorhead JF
    Kidney Int; 1993 Nov; 44(5):1124-9. PubMed ID: 8264145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin.
    Larsson PT; Wallén NH; Hjemdahl P
    Circulation; 1994 May; 89(5):1951-7. PubMed ID: 8181117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crossover trial of simvastatin versus pravastatin in patients with primary hypercholesterolemia.
    Sasaki S; Sawada S; Nakata T; Itoh H; Takeda K; Nakagawa M; Kuriyama K
    J Cardiovasc Pharmacol; 1997 Jul; 30(1):142-7. PubMed ID: 9268234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
    Dart A; Jerums G; Nicholson G; d'Emden M; Hamilton-Craig I; Tallis G; Best J; West M; Sullivan D; Bracs P; Black D
    Am J Cardiol; 1997 Jul; 80(1):39-44. PubMed ID: 9205017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M; Bonnefous F; Debbas N; Irvine A
    Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
    Aviram M; Hussein O; Rosenblat M; Schlezinger S; Hayek T; Keidar S
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):39-45. PubMed ID: 9456275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group.
    Am J Cardiol; 1993 Jun; 71(16):1408-14. PubMed ID: 8517385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.